Originally, MYSM1 was discovered as a regulator of androgen receptor-dependent gene activation in prostate cancer [31], and more recently, has also been implicated in poor outcomes of colorectal cancer [32] and in melanoma growth [33]. This evidence concerns the gene MYSM1 and melanoma.